The HINT3 Knockout A-549 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population of A-549 cells with targeted disruption of the HINT3 gene. This polyclonal pool preserves cellular heterogeneity while ensuring efficient gene inactivation, making it an ideal system for investigating HINT3 function in tumor suppression and mitochondrial biology. Generated via CRISPR/Cas9-mediated genome editing, the cell population eliminates the need for single-cell cloning, reducing clonal variability and accelerating experimental timelines.
A-549 cells are an adherent epithelial cell line originally isolated from the lung carcinoma tissue of a 58-year-old Caucasian male. Widely employed as a type II alveolar epithelial model, these cells are a cornerstone of non-small cell lung cancer (NSCLC) and adenocarcinoma research. Their well-characterized signaling networks, including p53, RAS, and EGFR pathways, make them highly suitable for dissecting oncogenic mechanisms and therapeutic responses. The A-549 background provides a clinically relevant platform for studying HINT3??s role in lung tumorigenesis.
HINT3 encodes a mitochondrial histidine triad nucleotide-binding protein that functions as a tumor suppressor, with key roles in apoptosis regulation and mitochondrial homeostasis. Mechanistically, HINT3 is positioned within p53-mediated apoptotic signaling, where it influences the expression and activity of downstream effectors such as BAX and BCL2, thereby modulating cytochrome c release and caspase-9 activation. It interacts with mitochondrial chaperones like HSPA9 and MICOS complex components to maintain mitochondrial integrity. Additionally, HINT3 suppresses cell migration by regulating E-cadherin and matrix metalloproteinase MMP9, linking mitochondrial function to cell adhesion dynamics. Loss of HINT3 is predicted to impair mitochondrial-mediated apoptosis and enhance invasive potential.
In A-549 lung adenocarcinoma cells, disruption of HINT3 creates a valuable model for examining how mitochondrial tumor suppressor defects drive malignancy. The knockout is expected to recapitulate aspects of aggressive NSCLC, including enhanced survival signaling and increased migratory and invasive capacity. By uncoupling HINT3 from its normal tumor-suppressive roles, researchers can investigate the resulting alterations in p53-dependent apoptosis, mitochondrial permeability transition, and cell-matrix adhesion. This model enables the dissection of HINT3??s context-specific functions in a lung epithelial environment, complementing existing in vitro and in vivo cancer studies.
The HINT3 Knockout A-549 Polyclonal Cells support a broad range of experimental applications. They are ideally suited for functional validation of HINT3??s tumor suppressor activity using apoptosis assays (Annexin V/PI flow cytometry), cell viability screens, and Western blotting analysis of Bax, Bcl-2, and cleaved caspase-3 levels. Migration and invasion can be quantified by Transwell assays, while mitochondrial health may be assessed via JC-1 staining for membrane potential. RT-qPCR and immunofluorescence facilitate gene expression and localization studies. Additionally, these cells serve in drug response profiling against chemotherapeutics such as cisplatin and paclitaxel, and co-immunoprecipitation assays enable probing of HINT3 interactions with HSPA9 or MICOS subunits. For technical support or ordering inquiries, contact Ascent Research.
